Illumina, Inc. Share Price

Equities

ILMN

US4523271090

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
108.7 USD -0.51% Intraday chart for Illumina, Inc. -4.43% -21.96%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 4.51B 356B Sales 2025 * 4.89B 386B Capitalization 17.3B 1,365B
Net income 2024 * -292M -23.02B Net income 2025 * 313M 24.68B EV / Sales 2024 * 3.86 x
Net Debt 2024 * 128M 10.09B Net cash position 2025 * 653M 51.47B EV / Sales 2025 * 3.41 x
P/E ratio 2024 *
-46.9 x
P/E ratio 2025 *
-11,283 x
Employees 10,615
Yield 2024 *
-
Yield 2025 *
-
Free-Float 79.71%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.51%
1 week-4.43%
Current month+4.20%
1 month-5.99%
3 months-15.18%
6 months-17.36%
Current year-21.96%
More quotes
1 week
107.15
Extreme 107.15
116.78
1 month
100.09
Extreme 100.085
119.00
Current year
100.09
Extreme 100.085
148.19
1 year
89.00
Extreme 89
212.49
3 years
89.00
Extreme 89
526.00
5 years
89.00
Extreme 89
555.77
10 years
89.00
Extreme 89
555.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 24/09/23
Chief Tech/Sci/R&D Officer - 31/12/97
Chief Tech/Sci/R&D Officer 54 13/03/22
Members of the board TitleAgeSince
Director/Board Member 58 28/11/12
Chairman 60 01/06/23
Director/Board Member 64 26/01/17
More insiders
Date Price Change Volume
14/06/24 108.7 -0.51% 1,605,903
13/06/24 109.2 +0.65% 1,891,097
12/06/24 108.5 -3.62% 2,147,737
11/06/24 112.6 +2.52% 2,762,624
10/06/24 109.8 -3.41% 3,751,830

Delayed Quote Nasdaq, June 14, 2024 at 09:00 pm

More quotes
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
108.7 USD
Average target price
152.1 USD
Spread / Average Target
+39.97%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW